Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raphael Gottardo

Showing results (171-180 of 187) with videos related to

Pageof 19
Sort By:
Plos One|October 3, 2013
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trialRaphael Gottardo, Robert T Bailer, Bette T Korber, et al.
Nature Methods|June 14, 2024
The tidyomics ecosystem: enhancing omic data analysesWilliam J Hutchison, Timothy J Keyes, , et al.
Biorxiv : the Preprint Server for Biology|December 3, 2025
Orchestrating Spatial Transcriptomics Analysis with BioconductorHelena L Crowell, Yixing Dong, Ilaria Billato, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2024
The <i>tidyomics</i> ecosystem: Enhancing omic data analysesWilliam J Hutchison, Timothy J Keyes, , et al.
The Journal of Clinical Investigation|October 8, 2019
Antibody Fc effector functions and IgG3 associate with decreased HIV-1 riskScott D Neidich, Youyi Fong, Shuying S Li, et al.
Immunity|September 18, 2020
A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the LiverLawrence T Wang, Lais S Pereira, Yevel Flores-Garcia, et al.
The Journal of Clinical Investigation|August 9, 2014
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trialShuying S Li, Peter B Gilbert, Georgia D Tomaras, et al.
Plos One|April 27, 2018
Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvantYingxia Wen, Hung V Trinh, Christine E Linton, et al.
Nature|December 20, 2013
Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIVMario Roederer, Brandon F Keele, Stephen D Schmidt, et al.
AIDS Research and Human Retroviruses|October 6, 2012
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120Nicos Karasavvas, Erik Billings, Mangala Rao, et al.
Pageof 19

Showing results (171-180 of 187) with videos related to

Sort By:
Pageof 19
Plos One|October 3, 2013
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trialRaphael Gottardo, Robert T Bailer, Bette T Korber, et al.
Nature Methods|June 14, 2024
The tidyomics ecosystem: enhancing omic data analysesWilliam J Hutchison, Timothy J Keyes, , et al.
Biorxiv : the Preprint Server for Biology|December 3, 2025
Orchestrating Spatial Transcriptomics Analysis with BioconductorHelena L Crowell, Yixing Dong, Ilaria Billato, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2024
The <i>tidyomics</i> ecosystem: Enhancing omic data analysesWilliam J Hutchison, Timothy J Keyes, , et al.
The Journal of Clinical Investigation|October 8, 2019
Antibody Fc effector functions and IgG3 associate with decreased HIV-1 riskScott D Neidich, Youyi Fong, Shuying S Li, et al.
Immunity|September 18, 2020
A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the LiverLawrence T Wang, Lais S Pereira, Yevel Flores-Garcia, et al.
The Journal of Clinical Investigation|August 9, 2014
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trialShuying S Li, Peter B Gilbert, Georgia D Tomaras, et al.
Plos One|April 27, 2018
Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvantYingxia Wen, Hung V Trinh, Christine E Linton, et al.
Nature|December 20, 2013
Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIVMario Roederer, Brandon F Keele, Stephen D Schmidt, et al.
AIDS Research and Human Retroviruses|October 6, 2012
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120Nicos Karasavvas, Erik Billings, Mangala Rao, et al.
Pageof 19